Companies /Healthcare

PTC Therapeutics Inc

NASDAQ: PTCT Biotechnology
$67.57
▼ $1.24 (−1.80%) today
Markets closed · 1:32am ET
Today · % change

Fundamentals

Market Cap
$5.6B
Profit Margin
-3.8%
Revenue (TTM)
$1.0B
EPS (TTM)
$-0.67
52-Week Range
$57 – $91
Street Target
$99.29

About PTC Therapeutics

PTC Therapeutics Inc is a pioneering biopharmaceutical company dedicated to developing innovative medicines for people with rare disorders. With a global presence, it offers treatments for conditions like Duchenne muscular dystrophy, spinal muscular atrophy, and other rare diseases. Its product lineup includes Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi. The company is also advancing research in areas such as Huntington’s disease and amyotrophic lateral sclerosis through its development pipeline. Founded in 1998 and based in South Plainfield, New Jersey, PTC Therapeutics collaborates with leading healthcare organizations to enhance its reach and impact.

PTCT Coverage